Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-002323
Filing Date
2025-05-14
Accepted
2025-05-14 16:10:14
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8131
2 JOINT FILING AGREEMENT p25-0949exhibit99_1.htm EX-99.1 3088
  Complete submission text file 0000902664-25-002323.txt   13145
Mailing Address 3 PLEASANT STREET, SUITE 400 C/O MATRIX CAPITAL MANAGEMENT PORTSMOUTH NH 03801
Business Address 3 PLEASANT STREET, SUITE 400 C/O MATRIX CAPITAL MANAGEMENT PORTSMOUTH NH 03801 781-522-4948
Matrix Capital Management Company, LP (Filed by) CIK: 0001410830 (see all company filings)

EIN.: 043475951 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Subject) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94841 | Film No.: 25945543
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)